Do GLP-1s work for Parkinson’s? A health tech startup pitches pharma on quick answers

feature-image

Play all audios:

NEW YORK — On the 77th floor of One World Trade Center, in an office with panoramic views of Manhattan, executives from pharma and biotech companies like Regeneron and Merck heard the pitch:


Please help us study GLP-1s in Parkinson’s disease.


With the explosion in popularity of diabetes and weight loss drugs like Ozempic and Zepbound, GLP-1 receptor agonist drugs have been hyped as potential miracle cures for many diseases.


GLP-1s are being studied for cardiovascular disease, liver conditions, kidney disease, and Alzheimer’s. Older approved GLP-1s from Novo Nordisk, Sanofi, and Amylin have been or are being


explored for Parkinson’s.


But amid all the jostling to find the next use case for GLP-1s, the proposition in October — the day before the Michael J. Fox Foundation’s annual meeting in New York — came from an unlikely


source: Koneksa Health, which helps drug developers use smartphone apps and wearables to study whether their treatments work. Koneksa hatched a plan to study GLP-1 with its tools after


researchers in April published results of a randomized control trial showing that people with Parkinson’s on Sanofi GLP-1 drug Lixisenatide saw no worsening of motor symptoms over a year,


compared to those on placebo who did. 


Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.